Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

Peers: ZTS IDXX ABT MRK SNY PETS BIIB VET RDFN

| Held by: IJH VTI VB VBR VXF MDY XMHQ DFAT IJK SPMD

Index	-	P/E	344.72	EPS (ttm)	0.07	Insider Own	0.92%	Shs Outstand	496.83M	Perf Week	-0.28%
Market Cap	12.49B	Forward P/E	24.50	EPS next Y	1.03	Insider Trans	0.96%	Shs Float	492.28M	Perf Month	2.82%
Enterprise Value	16.01B	PEG	3.07	EPS next Q	0.11	Inst Own	111.84%	Short Float	4.72%	Perf Quarter	13.97%
Income	36.00M	P/S	2.72	EPS this Y	2.53%	Inst Trans	0.78%	Short Ratio	4.61	Perf Half Y	39.61%
Sales	4.59B	P/B	1.85	EPS next Y	9.92%	ROA	0.27%	Short Interest	23.23M	Perf YTD	11.05%
Book/sh	13.58	P/C	24.72	EPS next 5Y	7.98%	ROE	0.54%	52W High	26.08 -3.62%	Perf Year	115.52%
Cash/sh	1.02	P/FCF	33.93	EPS past 3/5Y	- 29.95%	ROIC	0.34%	52W Low	8.02 213.34%	Perf 3Y	92.71%
Dividend Est.	-	EV/EBITDA	17.57	Sales past 3/5Y	-2.33% 7.65%	Gross Margin	43.32%	Volatility	2.93% 3.05%	Perf 5Y	-15.53%
Dividend TTM	-	EV/Sales	3.49	EPS Y/Y TTM	-82.39%	Oper. Margin	5.25%	ATR (14)	0.76	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	1.23	Sales Y/Y TTM	3.08%	Profit Margin	0.78%	RSI (14)	57.48	Recom	1.56
Dividend Gr. 3/5Y	- -	Current Ratio	2.40	EPS Q/Q	-109.35%	SMA20	1.93%	Beta	1.84	Target Price	26.42
Payout	0.00%	Debt/Eq	0.60	Sales Q/Q	10.39%	SMA50	7.47%	Rel Volume	0.66	Prev Close	24.79
Employees	9450	LT Debt/Eq	0.59	Earnings	Feb 24 BMO	SMA200	34.51%	Avg Volume	5.04M	Price	25.13
IPO	Sep 20, 2018	Option/Short	Yes / Yes	EPS/Sales Surpr.	46.15% 4.14%	Trades		Volume	3,343,477	Change	1.37%

Date	Action	Analyst	Rating Change	Price Target Change
Jan-22-26	Upgrade	Piper Sandler	Neutral → Overweight
Dec-09-25	Initiated	Barclays	Overweight	$30
Nov-21-25	Initiated	KeyBanc Capital Markets	Overweight	$27
Nov-19-25	Upgrade	Argus	Hold → Buy	$25
Oct-07-25	Upgrade	JP Morgan	Neutral → Overweight	$24
Jul-17-25	Upgrade	Leerink Partners	Market Perform → Outperform	$18
Jun-26-25	Upgrade	William Blair	Mkt Perform → Outperform
Dec-09-24	Initiated	UBS	Buy	$18
Dec-02-24	Initiated	Leerink Partners	Market Perform	$14
Sep-19-24	Downgrade	Morgan Stanley	Overweight → Equal-Weight	$17 → $15
Jan-05-24	Upgrade	Stifel	Hold → Buy	$13 → $20
Dec-19-23	Initiated	Jefferies	Buy	$17
Dec-15-23	Upgrade	Morgan Stanley	Equal-Weight → Overweight	$16
Dec-07-23	Initiated	Exane BNP Paribas	Outperform	$18
Apr-20-23	Upgrade	Barclays	Equal Weight → Overweight	$14
Aug-18-22	Downgrade	Morgan Stanley	Overweight → Equal-Weight	$37 → $22
Aug-16-22	Downgrade	JP Morgan	Overweight → Neutral	$28 → $24
Jul-21-22	Downgrade	Goldman	Buy → Sell	$32 → $19
Jul-12-22	Initiated	Piper Sandler	Neutral	$22
Nov-18-21	Initiated	Morgan Stanley	Overweight	$40

Show Previous Ratings

Feb-13-26 09:24AM	Elanco Announces Updates to Board of Directors (PR Newswire)
Feb-10-26 06:41AM	Here's What the Street Thinks About Elanco Animal Health Incorporated (ELAN) (Insider Monkey)
Jan-30-26 11:56AM	Can Operational Execution Support DaVita's Q4 Performance? (Zacks)
Jan-28-26 07:50AM	Hardman Johnston Global Equity Strategy Initiated a Position in Elanco Animal Health (ELAN) (Insider Monkey)
Jan-27-26 04:04PM	Gold and Silver Arent the Only Hot Commodities. Agricultural Stocks to Consider. (Barrons.com)
11:35PM	Loading…
Jan-26-26 11:35PM	2 Profitable Stocks to Own for Decades and 1 Facing Headwinds (StockStory)
Jan-22-26 04:36PM	Stocks Settle Higher as Global Tensions Cool and the Economy Expands (Barchart)
08:00AM	Elanco Confirms Date and Conference Call for Fourth Quarter and Full Year 2025 Financial Results Announcement (PR Newswire)
06:00AM	Companies Move to Refinance Sooner: Better Off to Lock It In (The Wall Street Journal)
Jan-12-26 06:54PM	Elanco CEO: Gaining Market Share Via 'Major' Innovations (Bloomberg)
Jan-06-26 11:08PM	3 Reasons to Avoid ELAN and 1 Stock to Buy Instead (StockStory)
06:52PM	Analyst Report: Elanco Animal Health Incorporated (Morningstar Research)
08:00AM	Elanco to Participate in the 44th Annual J.P. Morgan Healthcare Conference (PR Newswire)
Dec-31-25 02:00PM	Elanco Receives USDA Approval for Befrena (tirnovetmab), a New Anti-IL31 Monoclonal Antibody Injection Targeting Canine Allergic and Atopic Dermatitis (PR Newswire)
Dec-21-25 10:07AM	Jim Cramer on Elanco Animal Health: "They Are Doing Everything Right" (Insider Monkey)
01:30AM	Loading…
Dec-19-25 01:30AM	Elanco CEO Bites Off More Shares of Fast-Rising Stock (Barrons.com)
Dec-18-25 08:43AM	Elanco's Credelio Quattro-CA1 (lotilaner, moxidectin, praziquantel, and pyrantel chewable tablets) Receives First FDA Conditional Approval for Treatment of New World Screwworm in Dogs (PR Newswire)
Dec-16-25 02:05PM	Elanco (ELAN) Stock Is Up, What You Need To Know (StockStory)
09:40AM	Are Medical Stocks Lagging Elanco Animal Health (ELAN) This Year? (Zacks)
Dec-12-25 12:00PM	All You Need to Know About Elanco Animal Health (ELAN) Rating Upgrade to Buy (Zacks)
Dec-09-25 04:15PM	How Protein And Pets Drove Elanco Animal Health's Double-Digit Gain In 2025 (Investor's Business Daily) -5.81%
07:40AM	Elanco Investor Day Defines New Era as Sustainable Growth Company (PR Newswire)
Nov-24-25 07:00PM	Elanco, AMN Healthcare Services, Brookdale, DexCom, and Addus HomeCare Shares Skyrocket, What You Need To Know (StockStory)
Nov-21-25 01:35PM	Elanco's Credelio CAT (lotilaner) Receives First FDA Emergency Use Authorization (EUA) for Treatment of New World Screwworm (NWS) in Cats (PR Newswire)
Nov-20-25 08:00AM	Elanco to Participate in the Upcoming Investor Conferences (PR Newswire)
Nov-14-25 09:03AM	Pet Healthcare Spending Is Soaring. These 5 Stocks Are Positioned to Clean Up (24/7 Wall St.)
Nov-13-25 08:00AM	Alloy Partners Launches OneHealth Studio to Create Startups at the Convergence of Animal, Plant and Human Health (PR Newswire)
Nov-12-25 12:35AM	5 Revealing Analyst Questions From Elanco's Q3 Earnings Call (StockStory)
Nov-11-25 08:46AM	Are Options Traders Betting on a Big Move in Elanco Animal Health Stock? (Zacks)
Nov-06-25 12:33AM	ELAN Q3 Deep Dive: Innovation Drives Growth, but Market Eyes Margin and Competition (StockStory)
07:26PM	Loading…
Nov-05-25 07:26PM	Analyst Report: Elanco Animal Health Incorporated (Morningstar Research)
03:12PM	Elanco Animal Health CEO: Seeing a willingness to spend, durability even in 'consumer tested' time (CNBC TV)
02:01PM	Elanco Animal Health Inc (ELAN) Q3 2025 Earnings Call Highlights: Strong Revenue Growth and ... (GuruFocus.com)
09:30AM	Compared to Estimates, Elanco Animal Health (ELAN) Q3 Earnings: A Look at Key Metrics (Zacks)
07:35AM	Elanco Animal Health Incorporated (ELAN) Q3 Earnings and Revenues Surpass Estimates (Zacks)
06:36AM	Elanco (NYSE:ELAN) Surprises With Q3 Sales (StockStory)
06:27AM	Elanco Animal Health Reports Third Quarter 2025 Results (PR Newswire)
Nov-03-25 10:19PM	Elanco (ELAN) To Report Earnings Tomorrow: Here Is What To Expect (StockStory)
04:28PM	How Idexx Laboratories Business Shook Off Bears And Hit A Record (Investor's Business Daily)
Oct-29-25 10:00AM	Elanco Animal Health Incorporated (ELAN) Reports Next Week: What You Should Expect (Zacks)
Oct-28-25 11:27AM	Can Technology and Cost Discipline Lift DaVita's Q3 Earnings? (Zacks)
Oct-27-25 06:27AM	Elanco Announces Expansion of Credelio Quattro (lotilaner, moxidectin, praziquantel, and pyrantel chewable tablets) and Credelio (lotilaner) Labels, Offering Protection Against Lyme Disease and an Emerging Tick Species (PR Newswire)
Oct-24-25 05:33PM	Elanco Animal Health Obtains FDA Authorization for Screwworm Treatment (The Wall Street Journal)
04:55PM	Elanco's Credelio (lotilaner) Receives First Ever FDA Emergency Use Authorization (EUA) against New World Screwworm (NWS) in Dogs (PR Newswire)
12:02AM	Elanco (ELAN): Buy, Sell, or Hold Post Q2 Earnings? (StockStory)
Oct-23-25 11:40AM	ELAN vs. USPH: Which Stock Is the Better Value Option? (Zacks)
Oct-22-25 09:40AM	Is Elanco Animal Health (ELAN) Stock Outpacing Its Medical Peers This Year? (Zacks)
Oct-20-25 02:03PM	West Pharmaceutical Services Stock Sees RS Rating Climb To 71 (Investor's Business Daily)
Oct-17-25 06:39PM	Analyst Report: Elanco Animal Health Incorporated (Morningstar Research)
Oct-16-25 04:32PM	Elanco to Host Investor Day on December 9 (PR Newswire)
Oct-08-25 12:00PM	Elanco Animal Health Incorporated (ELAN) is a Great Momentum Stock: Should You Buy? (Zacks)
Oct-07-25 11:31AM	Why Elanco (ELAN) Stock Is Trading Up Today (StockStory)
Oct-06-25 11:40AM	ELAN or USPH: Which Is the Better Value Stock Right Now? (Zacks)
05:15AM	Best Value Stocks to Buy for October 6th (Zacks)
Oct-01-25 08:00AM	Elanco Confirms Date and Conference Call for Third Quarter 2025 Financial Results Announcement (PR Newswire)
Sep-30-25 12:00PM	Elanco Animal Health (ELAN) Upgraded to Buy: What Does It Mean for the Stock? (Zacks)
Sep-24-25 12:01PM	Why Elanco (ELAN) Stock Is Up Today (StockStory)
Sep-23-25 07:10PM	Elanco Animal Health Incorporated (ELAN) Joins S&P MidCap 400 Following Strong Q2 Growth and Product Ramp-Up (Insider Monkey)
06:27AM	Elanco Announces FDA Approves Improved Zenrelia (ilunocitinib tablets) Label, Removing Vaccine-Induced Disease Language (PR Newswire)
Sep-11-25 10:57PM	Analyst Report: Elanco Animal Health Incorporated (Morningstar Research)
Sep-08-25 03:35PM	Why Elanco (ELAN) Stock Is Trading Up Today (StockStory)
06:27AM	Elanco Innovation Builds Momentum, Credelio Quattro (lotilaner, moxidectin, praziquantel, and pyrantel chewable tablets) Reaches Blockbuster Status (PR Newswire)
Sep-03-25 02:45PM	Why Elanco (ELAN) Stock Is Trading Lower Today (StockStory)
Sep-01-25 11:31PM	Unpacking Q2 Earnings: Elanco (NYSE:ELAN) In The Context Of Other Pharmaceuticals Stocks (StockStory)
Aug-27-25 12:31PM	Why Elanco (ELAN) Stock Is Trading Up Today (StockStory)
08:00AM	Splenda Joins Elanco and HATCH to Support 'Nutrition Secure Indianapolis' to Strengthen Family Health Through Nutrition and Education (PR Newswire)
Aug-26-25 06:15PM	Elanco Animal Health Set to Join S&P MidCap 400; Sarepta Therapeutics to Join S&P SmallCap 600 (PR Newswire)
08:00AM	Elanco to Participate in Morgan Stanley 23rd Annual Global Healthcare Conference (PR Newswire)
Aug-14-25 01:34AM	5 Insightful Analyst Questions From Elanco's Q2 Earnings Call (StockStory)
Aug-12-25 03:25AM	ELAN Q2 Deep Dive: Innovation and Execution Drive Raised Full-Year Outlook (StockStory)
Aug-08-25 06:57PM	Analyst Report: Elanco Animal Health Incorporated (Morningstar Research)
11:53AM	Elanco (ELAN) Jumps 19.7% to Record High on Earnings Boost (Insider Monkey)
Aug-07-25 02:13PM	Elanco (NYSE:ELAN) Delivers Impressive Q2, Stock Jumps 15.4% (StockStory) +18.14%
12:23PM	Elanco Animal Health Soars Past 52-Week High On Strong Sales, Raised Annual Outlook (Benzinga)
09:30AM	Elanco Animal Health (ELAN) Reports Q2 Earnings: What Key Metrics Have to Say (Zacks)
07:35AM	Elanco Animal Health Incorporated (ELAN) Q2 Earnings and Revenues Beat Estimates (Zacks)
06:59AM	Elanco Animal Health Raises 2025 Guidance (RTT News)
06:27AM	Elanco Animal Health Reports Second Quarter 2025 Results (PR Newswire)
Aug-06-25 06:15PM	U.S. Physical Therapy (USPH) Tops Q2 Earnings and Revenue Estimates (Zacks)
09:15AM	Curious about Elanco Animal Health (ELAN) Q2 Performance? Explore Wall Street Estimates for Key Metrics (Zacks)
Aug-05-25 11:11PM	What To Expect From Elanco's (ELAN) Q2 Earnings (StockStory)
Aug-04-25 05:45PM	Addus HomeCare (ADUS) Surpasses Q2 Earnings and Revenue Estimates (Zacks)
Jul-31-25 01:16PM	Can Phosphate Binders Drive DaVita Stock Before Q2 Earnings? (Zacks)
Jul-25-25 03:36PM	Why Elanco (ELAN) Stock Is Trading Up Today (StockStory)
Jul-24-25 05:42PM	Elanco Secures Approval of Zenrelia (ilunocitinib) in the European Union (EU), Launching Innovative Canine Dermatology Treatment for Itchy Dogs (PR Newswire)
11:40AM	ELAN vs. USPH: Which Stock Is the Better Value Option? (Zacks)
Jul-22-25 09:40AM	Are Medical Stocks Lagging Encompass Health (EHC) This Year? (Zacks)
Jul-21-25 04:11AM	Veterinary Dermatology - Company Evaluation Report 2025 \| Zoetis, Elanco, and Boehringer Ingelheim Dominate with Global Reach, Innovative Portfolios, and Strategic Expansion (GlobeNewswire)
Jul-17-25 09:46AM	Starbucks downgraded, Oracle initiated: Wall Street's top analyst calls (The Fly)
Jul-15-25 10:35AM	Are Options Traders Betting on a Big Move in ELAN Stock? (Zacks)
Jul-10-25 08:00AM	Elanco Confirms Date and Conference Call for Second Quarter 2025 Financial Results Announcement (PR Newswire)
Jul-09-25 08:27AM	Elanco Receives USDA Approval for TruCan Ultra CIV H3N2/H3N8 (Canine Influenza Vaccine) Bringing to Market a High Standard of Respiratory Protection (PR Newswire)
Jul-02-25 07:00AM	Neurizon Enters into Global License with Elanco to Accelerate Commercialisation of NUZ-001 (PR Newswire)
Jun-30-25 07:25AM	5 Revealing Analyst Questions From Elanco's Q1 Earnings Call (StockStory)
Jun-26-25 01:00PM	Elanco Releases 2024 Impact Report and Introduces New Framework (PR Newswire)
09:49AM	General Mills upgraded, Trade Desk downgraded: Wall Street's top analyst calls (The Fly)
Jun-18-25 12:46PM	Zoetis Stock Is Falling. Why the Animal-Health Company Was Downgraded. (Barrons.com)
Jun-12-25 04:17PM	Elanco Receives Positive Opinion on Zenrelia (ilunocitinib) from EU's Committee for Veterinary Medicinal Products (CVMP) (PR Newswire)
Jun-11-25 04:25AM	ELAN Q1 Earnings Call: Innovation and Product Launches Drive Outlook Amid Macro Uncertainty (StockStory)
Jun-10-25 12:00PM	What Makes Elanco Animal Health (ELAN) a New Buy Stock (Zacks)

Elanco Animal Health, Inc. develops, manufactures, and markets products for pets and farm animals. Its products include Advantage Family, Atopica, Credelio Family, Drontal Family, Galliprant, Interceptor Plus, Milbemax, Onsior, Seresto, Trifexis, TruCan, AviPro, Baytril, Catosal, Denagard, and Experior. The company was founded in 1954 and is headquartered in Indianapolis, IN.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Kurzius Lawrence Erik	Director	Dec 12 '25	Buy	21.30	10,000	213,000	131,773	Dec 16 04:42 PM
Modi Rajeev A.	SEE REMARKS	Dec 11 '25	Buy	21.33	4,500	95,985	123,082	Dec 15 04:43 PM
VanHimbergen Robert M	EVP and CFO	Dec 11 '25	Buy	21.64	6,950	150,426	124,233	Dec 15 04:42 PM
Simmons Jeffrey N	PRESIDENT, CEO AND DIRECTOR	Dec 11 '25	Buy	21.75	22,000	478,496	167,000	Dec 15 04:41 PM
Todd S and Jennifer G Young Li	Former CFO	Aug 11 '25	Proposed Sale	16.82	49,333	830,000		Aug 11 03:58 PM
Kurzius Lawrence Erik	Director	Mar 07 '25	Buy	10.90	10,000	109,000	101,459	Mar 11 05:13 PM
Kurzius Lawrence Erik	Director	Mar 11 '25	Buy	10.20	10,000	102,000	111,459	Mar 11 05:13 PM
HOOVER R DAVID	Director	Mar 05 '25	Buy	10.90	25,000	272,558	210,000	Mar 07 04:21 PM

Open in Screener

NVCR

NovoCure Ltd

Feb 13 • 04:00PM ET

10.99

-1.54 -12.29 %

Healthcare • Medical Devices • United Kingdom • NASD

Peers: MDT BSX EW ISRG ZBH SYK TFX ALGN PEN RMD

| Held by: VTI VB IWM VBK VXF IWO IBB VTWO SCHA IHI

Index	RUT	P/E	-	EPS (ttm)	-1.61	Insider Own	10.00%	Shs Outstand	111.98M	Perf Week	8.38%
Market Cap	1.23B	Forward P/E	-	EPS next Y	-1.60	Insider Trans	0.73%	Shs Float	100.78M	Perf Month	-20.19%
Enterprise Value	992.58M	PEG	-	EPS next Q	-0.41	Inst Own	85.69%	Short Float	7.91%	Perf Quarter	-3.26%
Income	-177.65M	P/S	1.92	EPS this Y	10.17%	Inst Trans	2.03%	Short Ratio	4.45	Perf Half Y	-5.18%
Sales	642.27M	P/B	3.61	EPS next Y	-13.94%	ROA	-13.75%	Short Interest	7.97M	Perf YTD	-15.00%
Book/sh	3.05	P/C	1.19	EPS next 5Y	7.48%	ROE	-50.60%	52W High	22.95 -52.11%	Perf Year	-49.38%
Cash/sh	9.25	P/FCF	-	EPS past 3/5Y	-40.48% -83.87%	ROIC	-30.70%	52W Low	9.82 11.91%	Perf 3Y	-87.28%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	4.19% 11.49%	Gross Margin	75.52%	Volatility	11.32% 6.67%	Perf 5Y	-94.21%
Dividend TTM	-	EV/Sales	1.55	EPS Y/Y TTM	-15.64%	Oper. Margin	-27.37%	ATR (14)	1.00	Perf 10Y	-9.25%
Dividend Ex-Date	-	Quick Ratio	1.50	Sales Y/Y TTM	11.17%	Profit Margin	-27.66%	RSI (14)	42.24	Recom	1.57
Dividend Gr. 3/5Y	- -	Current Ratio	1.55	EPS Q/Q	-17.92%	SMA20	-9.12%	Beta	0.72	Target Price	25.21
Payout	-	Debt/Eq	2.34	Sales Q/Q	7.81%	SMA50	-14.06%	Rel Volume	1.99	Prev Close	12.53
Employees	1488	LT Debt/Eq	0.70	Earnings	Feb 26 BMO	SMA200	-21.52%	Avg Volume	1.79M	Price	10.99
IPO	Oct 02, 2015	Option/Short	Yes / Yes	EPS/Sales Surpr.	21.37% 5.20%	Trades		Volume	3,568,545	Change	-12.29%

Date	Action	Analyst	Rating Change	Price Target Change
Jul-25-25	Downgrade	Wells Fargo	Overweight → Equal Weight	$14.50
Jul-08-25	Initiated	Ladenburg Thalmann	Buy	$30
Dec-02-24	Upgrade	Evercore ISI	In-line → Outperform	$18 → $30
Oct-16-24	Upgrade	H.C. Wainwright	Neutral → Buy	$24 → $30
Nov-20-23	Resumed	JP Morgan	Neutral	$15
Aug-28-23	Downgrade	H.C. Wainwright	Buy → Neutral	$85 → $25
Aug-08-23	Upgrade	Piper Sandler	Neutral → Overweight	$45
Aug-04-23	Initiated	SVB Securities	Outperform	$51
Jul-31-23	Upgrade	Evercore ISI	Underperform → In-line	$33
Jun-07-23	Upgrade	Wedbush	Underperform → Neutral	$53 → $46
May-16-23	Upgrade	Wells Fargo	Equal Weight → Overweight	$70 → $104
Mar-17-23	Downgrade	JP Morgan	Neutral → Underweight	$99 → $50
Jan-06-23	Downgrade	Wells Fargo	Overweight → Equal Weight	$89 → $107
Jan-05-23	Reiterated	H.C. Wainwright	Buy	$100 → $140
Nov-29-22	Upgrade	Wells Fargo	Equal Weight → Overweight	$74 → $89
Oct-24-22	Downgrade	Piper Sandler	Overweight → Neutral	$90 → $70
Jul-05-22	Downgrade	Evercore ISI	In-line → Underperform
May-16-22	Initiated	H.C. Wainwright	Buy	$115
Feb-08-22	Initiated	Loop Capital	Buy	$200
Feb-02-22	Upgrade	Oppenheimer	Perform → Outperform	$98

Show Previous Ratings

Feb-13-26 07:42AM	Novocures stock rises 37% on FDA clearance of pancreatic cancer treatment device (Medical Device Network) -12.29%
06:00AM	Lyell starts first-of-its-kind CAR-T trial; New coalition aims to boost European biotechs (BioPharma Dive)
Feb-12-26 05:43PM	Novocure Is Up 19%. FDA Approval Is Giving the Biotech Stock a Lift. (Barrons.com) +19.33%
04:35PM	These Stocks Are Todays Movers: AppLovin, Fastly, Micron, Cisco, QuantumScape, Novocure, AST SpaceMobile, and More (Barrons.com)
04:15PM	Stocks to Watch Thursday Recap: Cisco, McDonalds, AppLovin (The Wall Street Journal)
03:11PM	Loading…
03:11PM	Stock Market Today: S&P 500 Breaks Key Support As Techs Pace Sell-Off; Cancer Stock Vaults (Live Coverage) (Investor's Business Daily)
11:26AM	NovoCure Stock Surges After FDA Approves Optune Pax (Benzinga)
10:07AM	Stocks to Watch Thursday: Cisco, McDonald's, AppLovin (The Wall Street Journal)
06:53AM	This Biotech Stock Is Jumping 25% After Getting an FDA Boost (Barrons.com)
06:28AM	AppLovin shares slide after earnings, and other early market movers (MarketWatch)
06:19AM	Stock Market Today: Dow Jones, S&P 500 Futures Gain After Strong Job Report-Micron, Novocure, Fastly In Focus (Benzinga)
04:50AM	Stock Market Today: Dow, S&P 500 and Nasdaq point higher as tech finds its footing; Treasurys steady; precious metals dip. (MarketWatch)
Feb-11-26 09:55PM	NovoCure (NVCR) Stock Is Trending Overnight - Here's What You Should Know (Benzinga)
06:33PM	Novocure Gets FDA Approval for Pancreatic Cancer Treatment; Shares Soar (The Wall Street Journal)
05:54PM	U.S. FDA Approves Novocure's Optune Pax for the Treatment of Locally Advanced Pancreatic Cancer (Business Wire)
08:10AM	Loading…
Feb-05-26 08:10AM	Bristol Myers Squibb (BMY) Tops Q4 Earnings and Revenue Estimates (Zacks) -12.72%
Jan-12-26 07:00AM	Novocure Announces Preliminary Full Year and Fourth Quarter 2025 Performance and Provides Company Update (Business Wire)
Jan-07-26 03:58AM	Moderna (MRNA) Soars 10.9%: Is Further Upside Left in the Stock? (Zacks)
Dec-22-25 07:00AM	Novocure to Present at 44th Annual J.P. Morgan Healthcare Conference (Business Wire)
Dec-09-25 05:31AM	Medtronic changes investor relations leadership ahead of diabetes spinout (MedTech Dive) +5.31%
Dec-01-25 07:00AM	Novocure Appoints Company President Frank Leonard as Chief Executive Officer (Business Wire) -8.82%
Nov-26-25 07:00AM	Novocure to Participate in 37th Annual Piper Sandler Healthcare Conference (Business Wire)
Nov-12-25 10:00AM	2 Healthcare Stocks for Individual Investors With a 40-Year Time Horizon (Motley Fool)
07:00AM	Novocure to Participate in 2025 Jefferies Global Healthcare Conference (Business Wire)
Oct-30-25 04:22PM	NovoCure Ltd (NVCR) Q3 2025 Earnings Call Highlights: Revenue Growth Amidst Challenges (GuruFocus.com)
10:30AM	Compared to Estimates, NovoCure (NVCR) Q3 Earnings: A Look at Key Metrics (Zacks)
08:20AM	NovoCure (NVCR) Reports Q3 Loss, Tops Revenue Estimates (Zacks)
07:17AM	NovoCure: Q3 Earnings Snapshot (Associated Press Finance)
07:00AM	Novocure Reports Third Quarter 2025 Financial Results (Business Wire)
Oct-15-25 07:00AM	Novocure to Present New Research for Tumor Treating Fields (TTFields) Therapy at European Association of Neuro-Oncology (EANO) Meeting and the European Society for Medical Oncology (ESMO) Congress (Business Wire) +7.67%
07:00AM	Loading…
Oct-01-25 07:00AM	Novocure to Report Third Quarter 2025 Financial Results (Business Wire) +8.20%
Sep-29-25 04:30PM	Novocure to Present Final Results from the Pivotal Phase 3 METIS Trial of its Tumor Treating Fields (TTFields) Therapy for Brain Metastases from Non-Small Cell Lung Cancer at 2025 ASTRO Annual Meeting (Business Wire)
Sep-16-25 05:28AM	Novocure obtains approval for Optune Lua device in Japan to treat NSCLC (Medical Device Network)
Sep-15-25 07:00AM	Novocure's Optune Lua Receives Approval in Japan for the Treatment of Unresectable Advanced/Recurrent Non-Small Cell Lung Cancer (NSCLC) (Business Wire)
Aug-29-25 04:26AM	2 Beaten-Down Stocks That Could Rocket 142% to 222% Higher, According to Wall Street Analysts (Motley Fool)
Aug-28-25 07:00AM	Novocure Announces Upcoming Investor Events (Business Wire)
Aug-25-25 07:00AM	Novocure Announces Coverage of Tumor Treating Fields (TTFields) Therapy for Patients with Newly Diagnosed Glioblastoma in Spain (Business Wire) -5.87%
Aug-22-25 01:37PM	NVCR Stock Slips Despite PMA Application to Treat Pancreatic Cancer (Zacks)
Aug-20-25 07:00AM	Novocure Submits Premarket Approval Application to FDA for Tumor Treating Fields Therapy in Locally Advanced Pancreatic Cancer (Business Wire)
Aug-13-25 12:08PM	Leerink Partners Reiterates a Buy Rating on NovoCure Limited (NVCR) (Insider Monkey)
Jul-25-25 07:02AM	NovoCure: Q2 Earnings Snapshot (Associated Press Finance)
Jul-24-25 01:30PM	NovoCure (NVCR) Reports Q2 Earnings: What Key Metrics Have to Say (Zacks) -24.05%
08:05AM	NovoCure (NVCR) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
07:00AM	Novocure Reports Second Quarter 2025 Financial Results (Business Wire)
Jul-01-25 07:00AM	Novocure to Present Final Secondary Endpoint Data from the Phase 3 PANOVA-3 Trial of Tumor Treating Fields (TTFields) in Pancreatic Cancer at the ESMO Gastrointestinal Cancers Congress 2025 (Business Wire)
Jun-30-25 09:32AM	NovoCure (NVCR) Soars 5.3%: Is Further Upside Left in the Stock? (Zacks)
07:00AM	Novocure to Report Second Quarter 2025 Financial Results (Business Wire)
Jun-18-25 12:00PM	What Makes NovoCure (NVCR) a New Buy Stock (Zacks)
Jun-06-25 12:26PM	NVCR Stock Dips Despite Positive OS Data From Phase 3 PANOVA-3 Trial (Zacks)
Jun-02-25 02:05PM	NovoCure's Tumor Treating Fields Boost One-Year And Pain-Free Survival In Pancreatic Cancer Trial (Benzinga) -10.83%
May-31-25 03:08PM	Zai Lab and Novocure Announce Results From the Phase 3 PANOVA-3 Trial of Tumor Treating Fields (TTFields) Therapy for Pancreatic Cancer to be Presented at 2025 ASCO Annual Meeting (Business Wire)
08:00AM	Results From the Phase 3 PANOVA-3 Trial of Novocure's Tumor Treating Fields (TTFields) Therapy for Pancreatic Cancer to be Presented at 2025 ASCO Annual Meeting (Business Wire)
May-28-25 06:57AM	1 Stock Down 35% This Year You'll Regret Not Buying on the Dip, According to Wall Street (Motley Fool)
May-27-25 07:00AM	Novocure Announces Upcoming Investor Events (Business Wire)
May-16-25 10:00AM	The Next Frontier to Treat Cancer: Electricity (The Wall Street Journal)
May-15-25 09:55AM	Does NovoCure (NVCR) Have the Potential to Rally 105.5% as Wall Street Analysts Expect? (Zacks)
Apr-29-25 09:55AM	Wall Street Analysts See a 91.92% Upside in NovoCure (NVCR): Can the Stock Really Move This High? (Zacks)
Apr-25-25 01:21PM	Why NovoCure Stock Skyrocketed This Week (Motley Fool)
Apr-24-25 07:03PM	Why NovoCure Stock Leaped 4% Higher Today (Motley Fool)
10:34AM	NovoCure Limited (NVCR) Q1 2025 Earnings Call Transcript (Seeking Alpha)
09:30AM	NovoCure (NVCR) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates (Zacks)
08:15AM	NovoCure (NVCR) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
07:13AM	NovoCure: Q1 Earnings Snapshot (Associated Press Finance)
07:00AM	Novocure Reports First Quarter 2025 Financial Results (Business Wire)
Apr-23-25 10:16AM	Novocure to Present Results from the Phase 3 PANOVA-3 Clinical Trial of its Tumor Treating Fields (TTFields) Therapy for Pancreatic Cancer as a Late-Breaking Oral Presentation at the 2025 ASCO Annual Meeting (Business Wire) +7.63%
06:45AM	Novocures device for metastatic NSCLC treatment gains CE Mark (Medical Device Network)
Apr-22-25 10:01AM	Exelixis (EXEL) Earnings Expected to Grow: What to Know Ahead of Q1 Release (Zacks) +5.97%
07:09AM	Novocure's Optune Lua Receives CE Mark Approval for the Treatment of Metastatic Non-Small Cell Lung Cancer (Business Wire)
Apr-17-25 10:01AM	NovoCure (NVCR) Expected to Beat Earnings Estimates: Can the Stock Move Higher? (Zacks)
Apr-16-25 03:43PM	Why NovoCure Stock Was Withering on Wednesday (Motley Fool)
Apr-10-25 08:40AM	Strength Seen in Bio-Techne (TECH): Can Its 10.8% Jump Turn into More Strength? (Zacks) -5.13%
Apr-01-25 07:00AM	Novocure to Report First Quarter 2025 Financial Results (Business Wire)
Mar-21-25 05:16PM	Zai Lab: Innovative Pharma Set For Strong Year Of Business (And Share Price) Growth (SeekingAlpha)
Mar-04-25 07:00AM	Novocure to Participate in Leerink Partners 2025 Global Healthcare Conference (Business Wire)
Feb-28-25 02:09AM	NovoCure Ltd (NVCR) Q4 2024 Earnings Call Highlights: Strong Revenue Growth Amidst Financial ... (GuruFocus.com)
Feb-27-25 03:30PM	NovoCure (NVCR) Q4 2024 Earnings Call Transcript (Motley Fool) -12.43%
10:00AM	NovoCure (NVCR) Reports Q4 Earnings: What Key Metrics Have to Say (Zacks)
08:20AM	NovoCure (NVCR) Reports Q4 Loss, Misses Revenue Estimates (Zacks)
07:20AM	NovoCure: Q4 Earnings Snapshot (Associated Press Finance)
07:00AM	Novocure Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Company Update (Business Wire)
Feb-20-25 10:00AM	NovoCure (NVCR) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release (Zacks)
Jan-30-25 03:14PM	Jim Cramer on NovoCure Limited (NVCR): I Have Watched Them For Years And Years And Theyre Not Making Money (Insider Monkey)
Jan-22-25 04:00AM	Novocure Inaugurates New Global Headquarters in Canton of Zug, Switzerland (Business Wire)
Jan-13-25 07:00AM	Novocure Announces Preliminary Full Year and Fourth Quarter 2024 Performance and Provides Company Update (Business Wire)
Jan-03-25 07:00AM	Novocure to Participate in 43rd Annual J.P. Morgan Healthcare Conference (Business Wire)
Dec-14-24 06:50AM	Novocure price target raised to $42 from $28 at Piper Sandler (TipRanks)
Dec-06-24 08:32AM	Why NovoCure Stock Was Winning Big This Week (Motley Fool) +5.11%
Dec-05-24 04:29AM	Novocure Has Already Doubled in 2024. Can It Soar Higher in 2025? (Motley Fool) -9.00%
Dec-03-24 02:51PM	Novocure Stock Earns 96 RS Rating (Investor's Business Daily)
07:17AM	Zai Lab, Novocure announce PANOVA-3 trial met primary endpoint (TipRanks)
Dec-02-24 04:23PM	Novocure Launches 49% After Pancreatic Cancer Treatment Succeeds (Investor's Business Daily) +48.95%
01:20PM	Novocure seeks approval after pancreatic cancer wearable scores at Phase III (Clinical Trials Arena)
10:12AM	NovoCure's Tumor-Treating Electric Fields Shows Promise In Pancreatic Cancer Patients (Benzinga)
09:54AM	Novocure's Stock Skyrockets Over 32% Amid Groundbreaking Pancreatic Cancer Therapy Success (GuruFocus.com)
07:02AM	Zai Lab and Novocure Announce Positive Topline Results from Phase 3 PANOVA-3 Clinical Trial of Tumor Treating Fields (TTFields) Therapy for Pancreatic Cancer (Business Wire)
07:00AM	Novocure Announces Positive Topline Results from Phase 3 PANOVA-3 Clinical Trial of Tumor Treating Fields (TTFields) Therapy for Pancreatic Cancer (Business Wire)
06:08AM	Novocure device succeeds in pancreatic cancer study; FDA sets Cytokinetics decision date (BioPharma Dive)
Nov-27-24 07:00AM	Novocure to Participate in Upcoming Investor Conferences (Business Wire) +10.12%
Nov-21-24 11:58AM	Novocure secures FDA approval for add-ons to brain cancer treatment wearable (Medical Device Network)
07:05AM	Novocure Data at 2024 SNO Annual Meeting Highlights Product Innovation and Real-World Evidence for Tumor Treating Fields (TTFields) Therapy in Glioblastoma (Business Wire)

NovoCure Ltd. is an oncology company which engages in the development, manufacture, and commercialization of Optune for the treatment of a variety of solid tumors. Its platform is called the Tumor Treating Field which uses electric fields tuned to specific frequencies to disrupt solid tumor cancer cell division. The company was founded by Yoram Palti in 2000 and is headquartered in St. Helier, Jersey.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Cordova Ashley	Chief Executive Officer	Sep 05 '25	Buy	12.22	81,550	996,859	437,569	Sep 08 07:10 AM
Brackmann Christoph	Chief Financial Officer	Jul 29 '25	Buy	11.59	20,000	231,800	141,150	Jul 30 04:33 PM
Stafford Kristin	Director	Jun 03 '25	Sale	17.28	999	17,259	3,054	Jun 04 04:26 PM
LEUNG GABRIEL	Director	Jun 03 '25	Sale	17.31	999	17,297	81,229	Jun 04 04:24 PM
Madden Martin J.	Director	Jun 03 '25	Sale	17.19	999	17,176	18,674	Jun 04 04:23 PM
Scannell Timothy J	Director	Jun 03 '25	Sale	17.32	999	17,299	6,018	Jun 04 04:22 PM
HILLEMAN JERYL L	Director	Jun 03 '25	Sale	17.26	999	17,247	5,591	Jun 04 04:17 PM
Ocean Allyson J	Director	Jun 03 '25	Sale	17.29	999	17,269	3,054	Jun 04 04:16 PM
VERNON W ANTHONY	Director	Jun 03 '25	Sale	17.35	999	17,329	167,887	Jun 04 04:14 PM
Hung David	Director	Jun 03 '25	Sale	17.30	999	17,280	12,195	Jun 04 04:11 PM
Leonard Frank X	EVP, Pres., Novocure Oncology	Jun 02 '25	Sale	17.50	30,196	528,413	168,452	Jun 04 04:09 PM
FRANCIS LEONARD	Officer	Jun 02 '25	Proposed Sale	19.11	30,196	577,046		Jun 02 04:25 PM
Paravasthu Mukund	Chief Operating Officer	May 03 '25	Sale	17.91	592	10,604	83,556	May 05 04:17 PM
MUKUND PARAVASTHU	Officer	May 05 '25	Proposed Sale	17.91	592	10,604		May 05 04:05 PM
Weinberg Uri	Chief Innovation Officer	Mar 03 '25	Sale	18.92	268	5,071	166,243	Mar 04 04:19 PM
Leonard Frank X	EVP, Pres., Novocure Oncology	Mar 03 '25	Sale	18.54	2,527	46,841	143,673	Mar 04 04:19 PM
Cordova Ashley	Chief Executive Officer	Mar 03 '25	Sale	18.54	2,053	38,055	204,005	Mar 04 04:19 PM
Paravasthu Mukund	Chief Operating Officer	Mar 03 '25	Sale	18.54	250	4,634	29,173	Mar 04 04:16 PM
FRANCIS LEONARD	Officer	Mar 03 '25	Proposed Sale	18.54	2,527	46,841		Mar 03 05:34 PM
MUKUND PARAVASTHU	Officer	Mar 03 '25	Proposed Sale	18.54	250	4,634		Mar 03 05:31 PM
URI WEINBERG	Officer	Mar 03 '25	Proposed Sale	18.92	268	5,071		Mar 03 05:20 PM
ASHLEY CORDOVA	Officer	Mar 03 '25	Proposed Sale	18.54	2,053	38,055		Mar 03 05:18 PM
WILHELMUS GROENHUYSEN	Officer	Mar 03 '25	Proposed Sale	18.54	3,165	58,667		Mar 03 05:13 PM
Weinberg Uri	Chief Innovation Officer	Feb 28 '25	Sale	18.75	4,637	86,949	166,511	Mar 03 04:28 PM
Leupin Nicolas	Chief Medical Officer	Feb 27 '25	Sale	20.02	991	19,844	50,133	Mar 03 04:28 PM
Puri Michal Nath	Chief Human Resources Officer	Feb 27 '25	Sale	20.02	1,387	27,773	108,706	Mar 03 04:27 PM
Leonard Frank X	EVP, Pres., Novocure Oncology	Feb 27 '25	Sale	20.02	12,266	245,609	148,970	Mar 03 04:27 PM
Leonard Frank X	EVP, Pres., Novocure Oncology	Feb 28 '25	Sale	18.28	2,770	50,648	146,200	Mar 03 04:27 PM
Cordova Ashley	Chief Executive Officer	Feb 27 '25	Sale	20.02	11,153	223,323	208,399	Mar 03 04:26 PM
Cordova Ashley	Chief Executive Officer	Feb 28 '25	Sale	18.28	2,341	42,804	206,058	Mar 03 04:26 PM
Paravasthu Mukund	Chief Operating Officer	Feb 27 '25	Sale	20.02	1,646	32,959	29,791	Mar 03 04:26 PM
Paravasthu Mukund	Chief Operating Officer	Feb 28 '25	Sale	18.28	368	6,729	29,423	Mar 03 04:26 PM
URI WEINBERG	Officer	Feb 28 '25	Proposed Sale	18.75	4,637	86,949		Feb 28 05:01 PM
MUKUND PARAVASTHU	Officer	Feb 28 '25	Proposed Sale	18.28	368	6,729		Feb 28 04:50 PM
ASHLEY CORDOVA	Officer	Feb 28 '25	Proposed Sale	18.28	2,341	42,803		Feb 28 04:43 PM
WILHELMUS GROENHUYSEN	Officer	Feb 28 '25	Proposed Sale	18.28	3,202	58,546		Feb 28 04:40 PM
FRANCIS LEONARD	Officer	Feb 28 '25	Proposed Sale	18.28	2,770	50,647		Feb 28 04:38 PM
MUKUND PARAVASTHU	Officer	Feb 27 '25	Proposed Sale	20.02	1,646	32,959		Feb 27 04:42 PM
ASHLEY CORODVA	Officer	Feb 27 '25	Proposed Sale	20.02	11,153	223,322		Feb 27 04:39 PM
WILHELMUS GROENHUYSEN	Officer	Feb 27 '25	Proposed Sale	20.02	7,211	144,389		Feb 27 04:36 PM
FRANCIS LEONARD	Officer	Feb 27 '25	Proposed Sale	20.02	12,266	245,608		Feb 27 04:28 PM

ELAN

Elanco Animal Health Inc

NVCR

NovoCure Ltd

Upgrade your FINVIZ experience